Fermenta Biotech Ltd

Fermenta Biotec. Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Fermenta Biotech Ltd

₹ 160 1.85%
05 Dec 10:56 a.m.
dil.net BSE: 506414
About

FBL, incorporated in 1986, has two business segments; i.e. manufacturing of active pharmaceutical ingredients (APIs) and lease rental business for commercial properties developed in Thane.

Key Points

Key Product Segments
The company’s business can be classified majorly under five segments which are Vitamin D3, specialty APIs, biological enzymes and biotech based environmental solutions and rental business. FBL manufactures a range of Vitamin D3 variants having an optimal mix between human and animal feed products. [1]

Website BSE
  • Market Cap ₹ 471 Cr.
  • Current Price ₹ 160
  • High / Low ₹ 210 / 103
  • Stock P/E
  • Book Value ₹ 105
  • Dividend Yield 0.79 %
  • ROCE 3.81 %
  • ROE 0.65 %
  • Face Value ₹ 5.00
Edit ratios

Pros

  • Company has reduced debt.
  • Company's working capital requirements have reduced from 176 days to 129 days

Cons

  • Company has low interest coverage ratio.
  • Company has a low return on equity of 7.78% over last 3 years.
  • Dividend payout has been low at 6.51% of profits over last 3 years

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs

Edit Columns
Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Sep 2020 Dec 2020 Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023
93 88 91 109 99 85 95 84 90 54 101 77 51
66 65 73 81 81 73 76 76 79 60 75 64 63
Operating Profit 28 23 18 28 18 12 19 8 11 -6 25 13 -12
OPM % 30% 26% 20% 25% 18% 14% 20% 9% 12% -11% 25% 17% -23%
1 1 4 1 2 1 3 4 3 -45 -14 2 -7
Interest 5 4 5 4 4 4 4 4 5 5 6 5 4
Depreciation 5 5 6 5 6 6 6 6 6 6 6 6 6
Profit before tax 19 15 11 19 9 3 11 1 3 -62 -1 5 -28
Tax % 20% 27% 11% 33% 31% 41% 18% 13% 21% 5% -173% 0% 0%
15 11 10 13 7 2 9 1 2 -59 -2 5 -28
EPS in Rs 5.08 3.75 3.29 4.35 2.23 0.62 3.08 0.36 0.72 -20.03 -0.72 1.63 -9.51
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 TTM
18 18 15 14 6 6 13 403 299 371 387 328 282
7 9 11 11 12 14 22 255 229 276 310 288 262
Operating Profit 11 9 4 3 -6 -8 -9 148 70 95 77 40 21
OPM % 60% 50% 28% 21% -99% -154% -75% 37% 24% 26% 20% 12% 7%
9 0 0 0 1 0 0 6 12 6 8 -52 -63
Interest 0 0 0 0 2 6 11 21 20 19 18 21 20
Depreciation 2 2 2 2 2 3 4 12 15 19 24 25 23
Profit before tax 18 7 2 1 -9 -18 -23 121 48 63 43 -59 -86
Tax % 20% 20% 31% 30% 1% -2% -3% 9% -34% 18% 29% 2%
15 5 1 1 -9 -18 -24 110 64 52 30 -58 -84
EPS in Rs 5.32 1.93 0.51 0.26 -3.31 -6.63 -8.75 40.13 21.63 17.66 10.27 -19.55 -28.63
Dividend Payout % 47% 96% 161% 157% -6% -3% -2% 1% 23% 14% 12% -6%
Compounded Sales Growth
10 Years: 34%
5 Years: 92%
3 Years: 3%
TTM: -20%
Compounded Profit Growth
10 Years: -8%
5 Years: 16%
3 Years: -66%
TTM: -221%
Stock Price CAGR
10 Years: 17%
5 Years: -13%
3 Years: -21%
1 Year: -15%
Return on Equity
10 Years: 11%
5 Years: 17%
3 Years: 8%
Last Year: 1%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Sep 2023
Equity Capital 2 2 2 2 2 2 2 5 14 14 14 14 14
Reserves 93 92 91 90 80 87 62 245 298 356 382 320 295
6 1 25 35 52 44 143 209 226 234 241 221 172
9 13 13 15 15 12 15 93 71 78 76 109 127
Total Liabilities 110 107 131 143 149 146 223 551 610 683 713 665 608
12 10 8 7 93 94 96 177 197 250 287 258 236
CWIP 5 13 34 63 1 1 0 22 71 57 35 45 49
Investments 36 32 39 40 41 40 118 8 1 13 13 16 4
57 53 51 33 15 12 9 344 341 363 378 346 320
Total Assets 110 107 131 143 149 146 223 551 610 683 713 665 608

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
31 11 2 -0 -5 -9 1 91 30 63 50 124
-25 -2 -20 -11 -8 20 -89 -97 -39 -44 -32 -64
-7 -8 21 9 14 -13 88 12 -48 -1 -22 -41
Net Cash Flow -0 1 2 -2 1 -2 1 6 -57 18 -4 19

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Debtor Days 5 12 9 5 2 26 8 59 94 95 111 75
Inventory Days 347 501 392 328 317
Days Payable 172 208 135 115 153
Cash Conversion Cycle 5 12 9 5 2 26 8 234 387 352 324 239
Working Capital Days -29 -14 -212 -923 -2,380 -538 -289 97 225 191 208 129
ROCE % 10% 7% 2% 1% -5% -9% -7% 45% 13% 14% 10% 4%

Shareholding Pattern

Numbers in percentages

Dec 2020Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023
59.44% 59.44% 59.44% 59.44% 59.58% 59.58% 59.58% 59.58% 59.58% 59.58% 62.06% 62.06%
0.25% 0.13% 0.03% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.00% 0.00% 0.00%
0.24% 0.24% 0.00% 0.00% 0.05% 0.05% 0.05% 0.05% 0.00% 0.00% 0.00% 0.00%
38.09% 38.21% 38.55% 38.57% 38.37% 38.37% 38.37% 38.38% 38.45% 38.46% 36.00% 36.04%
1.98% 1.98% 1.98% 1.98% 1.98% 1.98% 1.98% 1.98% 1.95% 1.95% 1.92% 1.89%
No. of Shareholders 13,53915,02715,54118,39918,57817,51817,47217,97117,61016,89716,14815,721

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings

Concalls